Half-year trading update

AI SummaryClose X

Novacyt S.A. reported a strong first half for 2026, with unaudited statutory revenue increasing by 18% to approximately £11.6 million, driven by 9% organic growth excluding the impact of Southern Cross Diagnostics (SCD). The Instrumentation segment saw 30% revenue growth, and the Clinical segment grew over 20%, with all three geographic regions experiencing year-on-year revenue increases. SCD contributed £1.8 million in revenue since its acquisition. Cash reserves stood at £8.9 million as of June 30, 2026, reflecting a £5.5 million outflow for the SCD acquisition. The company also raised approximately €785,000 gross through a rights issue and is progressing with a restructuring program expected to yield up to £4.0 million in annual cost savings.

Disclaimer*

UK 100

Latest directors dealings